Other targets that have been studied in MM, such as GPRC5D, FCHR5, and CS1/SLAM F7, may also be important in patients with AL amyloidosis, and novel therapies directed at these antigens may further expand the treatment armamentarium. The gene discussed is SLAMF1; the disease is Miyoshi myopathy.